Skip to content
value.today

CinCor Pharma, Inc.

🇺🇸 Cincinnati, Ohio, USABiotechnologyFounded 2018
Total raised
$143 M
1 round on record
Latest round
$143 M
Sep 2021
First round on record
Sep 2021
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of CinCor Pharma, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2021$143 MNo. 1$50 to $250 million

CinCor Pharma, Inc.: Raise no. 1, Sep 2021

Investors in this round

22 investors had bought by the notice of Oct 12, 2021: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 23 investors are named for CinCor Pharma, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$143 M of $143 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Marc de Garidel · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Marc de Garidel, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 12, 2021. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • CinCor Pharma, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2021).

    SEC Form D · Oct 2021

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2021

That is all the official record says: CinCor Pharma, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

23 named in official filings. Open an investor to see everything it has backed.

Investors in CinCor Pharma, Inc.
InvestorKindAmountRoundRoleSource
5AM Opportunities I (GP), LLCOthernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
5AM Opportunities I, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
5AM Partners VI, LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
5AM Ventures VI, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
CinRx Pharma, LLCOthernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
GAP (Bermuda) LTDCompanynot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
GAP Coinvestments CDA, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
Gap Coinvestments III LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
Gap Coinvestments IV LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
GAP Coinvestments V, LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
General Atlantic (CIN), L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
General Atlantic Genpar (bermuda), L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
General Atlantic Genpar, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
General Atlantic, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
General Atlantic (Lux) S.a r.l.Companynot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
General Atlantic Partners 100, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
General Atlantic Partners (Bermuda) EU, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
General Atlantic Partners (Lux), SCSpFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
General Atlantic (SPV) GP, LLCOthernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
Sofinnova Capital IXFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
Sofinnova Management X, L.L.C.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
Sofinnova Partners SASFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
Sofinnova Venture Partners X, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2022)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 22 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by CinCor Pharma, Inc.
NameRoleNamed in
Marc de GaridelExecutive officerOct 2021
Marc de GaridelDirectorOct 2021